A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-­polycythemia vera/essential thrombocythemia myelofibrosis (post-­PV/ET MF) von Mascarenhas, J., Marcellino, B.K., Lu, M., Kremyanskaya, M., Fabris, F., Sandy, L., Mehrotra, M., Houldsworth, J., Najfeld, V., El Jamal, S., Petersen, B., Moshier, E., Hoffman, R.

Volltext